Drug
Darbepoetin alfa clinical trials
Also written Aranesp, Darbepoetin and BCD-066.
Keep track of what changes. Save the Darbepoetin alfa studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
115 studies that test it; most in 2002 (20)
| Year | Studies |
|---|---|
| 1999 | 2 |
| 2000 | 2 |
| 2001 | 2 |
| 2002 | 20 |
| 2003 | 12 |
| 2004 | 14 |
| 2005 | 7 |
| 2006 | 11 |
| 2007 | 3 |
| 2008 | 5 |
| 2009 | 4 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 5 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 5 |
| 2018 | 1 |
| 2019 | 2 |
| 2021 | 3 |
| 2022 | 1 |
| 2025 | 4 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
- Anemia
- 12
Who runs them
Industry 73 · Other 50
Amgen (61) · Biocad (3) · Kyowa Kirin Co., Ltd. (3) · University of New Mexico (2) · M.D. Anderson Cancer Center (2) · Seoul National University Bundang Hospital (2) · University of Washington (2) · Institute of Liver and Biliary Sciences, India (2)
Often tested with
Tested in the same studies.
Epoetin Alfa (4) · Pegfilgrastim (3) · Roxadustat (2) · Canakinumab (1) · Filgrastim (1) · Paricalcitol (1) · R-CHOP Regimen (1) · Doxorubicin (1)
Studies
Open first, then newest update. How each study uses Darbepoetin alfa is read from its arms, and is right about nine times in ten.
Testing it · 123
- Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm InfantsRecruitingPhase 2University of WashingtonNCT05340465Written as Darbepoetin Alfa
- Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.RecruitingNot applicableInstitute of Liver and Biliary Sciences, IndiaNCT07002827Written as Darbepoetin
- Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite AthletesEnrolling by invitationNot applicableEnhanced Emirates LimitedNCT07568574Written as EPO Darbepoetin (Aranesp)
- Darbepoetin in Patients Candidates for Liver Transplant. (EPO-LT Trial)RecruitingPhase 3Fundacion Clinic per a la Recerca BiomédicaNCT07169643Written as Darbepoetin (DP)
- National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Single vs Repeated Cycle of Granulocyte Colony-Stimulating Factor (GCSF) & Darbepoetin in Early Decompensated CirrhosisNot yet recruitingNot applicableInstitute of Liver and Biliary Sciences, IndiaNCT07131280Written as Darbepoetin
- The Effect of Roxadustat on Renal Oxygenation in Diabetes NephropathyNot yet recruitingPhase 2Region StockholmNCT05810311Written as Darbepoietin Alfa
- Darbepoetin in Neonatal Encephalopathy TrialRecruitingPhase 2Imperial College LondonNCT04432662Written as Darbepoetin Alfa
- Darbepoetin for Ischemic Neonatal Stroke to Augment RegenerationRecruitingPhase 2UMC UtrechtNCT03171818Written as Darbepoetin Alfa
- Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm InfantsCompletedPhase 3NICHD Neonatal Research NetworkNCT03169881Written as Darbepoetin
- Mechanisms of EPO-induced HypertensionTerminatedPhase 2VA Office of Research and DevelopmentNCT03810911Written as Darbepoetin
- Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESAActive, not recruitingPhase 1/2H. Lee Moffitt Cancer Center and Research InstituteNCT04798339Written as Darbepoetin Alfa
- Darbepoetin Alfa Once Monthly Dosing Schedule Maintains Hemoglobin Concentration Comparable to Every 2 Weeks Dosing Schedule in Advanced Chronic Kidney Disease Patients Not on Dialysis: A Multicenter, Phase 4 StudyActive, not recruitingPhase 4Gangnam Severance HospitalNCT07025460Written as darbepoetin alfa
- Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic SyndromesCompletedPhase 3Barts & The London NHS TrustNCT01196715Written as Darbepoetin alpha
- A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With AnemiaCompletedPhase 3Astellas Pharma IncNCT02952092Written as Darbepoetin alfa
- Darbe Administration in Newborns Undergoing Cooling for EncephalopathyCompletedPhase 1/2University of UtahNCT01471015Written as Darbepoetin alfa
- Mild Encephalopathy in the Newborn Treated With DarbepoetinCompletedPhase 2University of New MexicoNCT03071861Written as Darbepoetin Alfa
- Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast CancerCompletedPhase 2Harold J. Burstein, MD, PhDNCT00146562Written as Darbepoetin Alfa
- Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving ChemotherapyTerminatedPhase 3AmgenNCT00858364Written as Darbepoetin alfa
- Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney DiseaseTerminatedPhase 3AmgenNCT00436748Written as Darbepoetin Alfa
- RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure TrialCompletedPhase 3AmgenNCT00358215Written as Darbepoetin alfa
See all 123 studies that test Darbepoetin alfa →
Given in every arm · 8 — Darbepoetin alfa is usual care beside what is tested
- Combination Therapy of Romiplostim and Erythropoiesis-stimulating AgentsRecruitingPhase 2Chinese University of Hong KongNCT07854561Written as darbepoetin alfa
- Luspatercept + Darbepoetin in MDSRecruitingPhase 2Yale UniversityNCT07096297Written as Darbeopoetin
- High Dose IV Iron Plus ESA in Chemotherapy-induced AnemiaRecruitingPhase 3Hallym University Medical CenterNCT05768997Written as Darbepoetin Alfa Injection
- Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell LymphomaCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT00058422Written as darbepoetin alfa
- A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)CompletedPhase 4Hoffmann-La RocheNCT00773513Written as Darbepoetin Alfa
- Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedPhase 2Alliance for Clinical Trials in OncologyNCT00077311Written as darbepoetin alfa
- Darbepoetin Alfa With or Without Intravenous (IV) IronCompletedPhase 2AmgenNCT00401544Written as darbepoetin alfa
- Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With CancerCompletedPhase 3Mayo ClinicNCT00661999Written as darbepoetin alfa
As the comparator · 49 — what is tested is compared with Darbepoetin alfa
- A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on DialysisRecruitingPhase 3Genexine, Inc.NCT06466785Written as Darbepoetin Alfa
- A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)Not yet recruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT07300111Written as Darbepoetin alfa
- Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in JapanCompletedPhase 3Tanabe Pharma CorporationNCT03329196Written as Darbepoetin alfa
- Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in JapanCompletedPhase 3Tanabe Pharma CorporationNCT03439137Written as Darbepoetin alfa
- Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)CompletedPhase 3Akebia TherapeuticsNCT04313153Written as Darbepoetin alfa
- Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable DialysisCompletedPhase 3Astellas Pharma Europe B.V.NCT02278341Written as Darbepoetin alfa
- Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin AlfaCompletedPhase 3Astellas Pharma Europe B.V.NCT02021318Written as Darbepoetin alfa
- A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference DrugCompletedPhase 2Astellas Pharma IncNCT01888445Written as darbepoetin alfa
- Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)CompletedPhase 3GlaxoSmithKlineNCT02876835Written as Darbepoetin alfa
- Anemia Study in Chronic Kidney Disease (CKD) : Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat -Forearm Blood Flow (ASCEND-FBF)TerminatedPhase 2GlaxoSmithKlineNCT03446612Written as Darbepoetin alfa
- Pharmacokinetics Comparison Study of JT1801 and NESP® After Single Dose Administration in Chinese Health Male VolunteersCompletedPhase 4Yi FangNCT05864261Written as NESP 60ug
- Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)CompletedPhase 3Akebia TherapeuticsNCT02865850Written as Darbepoetin alfa
- Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)CompletedPhase 3Akebia TherapeuticsNCT02892149Written as Darbepoetin alfa
- Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)CompletedPhase 3Akebia TherapeuticsNCT02680574Written as Darbepoetin alfa
- Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney DiseaseCompletedPhase 3Akebia TherapeuticsNCT02648347Written as Darbepoetin alfa
- Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)CompletedPhase 3GlaxoSmithKlineNCT03029208Written as Darbepoetin alfa
- A Study of Once Monthly Intravenous or Subcutaneous Mircera in Participants With Chronic Kidney Disease on Hemodialysis.CompletedPhase 3Hoffmann-La RocheNCT00717821Written as Darbepoetin Alfa
- A Study to Evaluate Efficacy and Safety of JTZ-951 Compared to Darbepoetin Alfa in Korean Renal Anemia Patients Receiving Hemodialysis.CompletedPhase 3JW PharmaceuticalNCT04027517Written as Darbepoetin Alfa
- Maintenance Treatment of Renal Anemia in Dialysis SubjectsCompletedPhase 3BayerNCT03543657Written as Darbepoetin alfa
- A Study of Molidustat for Correction of Renal Anemia in Non-dialysis SubjectsCompletedPhase 3BayerNCT03350321Written as Darbepoetin alfa
Showing 20 of 49.
Codes
What other systems call Darbepoetin alfa · ClinicalTrials.gg INT006503
- MeSH (NLM) D000068256Darbepoetin alfaConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 15UQ94PT4PDARBEPOETIN ALFAConfirmed FDA, NLM, Wikidata
- RxNorm 283838Confirmed FDA, Wikidata
- Wikidata Q2178381darbepoetin alfaConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1878Darbepoetin AlfaOne source FDA
- DrugBank DB00012One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000068256 | Darbepoetin alfa | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 15UQ94PT4P | DARBEPOETIN ALFA | Confirmed FDA, NLM, Wikidata |
| RxNorm | 283838 | — | Confirmed FDA, Wikidata |
| Wikidata | Q2178381 | darbepoetin alfa | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1878 | Darbepoetin Alfa | One source FDA |
| DrugBank | DB00012 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.